Consistently, stable co-knockdown of RAC1 in HACE1 deficient cells inhibits HIF1α accumulation in these cells, suggesting targeting of RAC1 is a potential mechanistic intervention point for targeted therapy in diverse cancer types. This evidence concerns the gene HACE1 and cancer.